Recently, after preliminary research, audit evaluation, submission of materials and other necessary links, our company successfully passed the audit and became the first batch of high-tech enterprises to be recognized in Shanghai in 2020!

The recognition of high-tech enterprises will bring new opportunities for our company to build innovative enterprises, so that the company can obtain more technical and policy support in the process of innovation and development, and is also another milestone in the company's development history. In the future, as a high-tech enterprise, Rocky Biology will continue to increase its investment in high-tech R&D and personnel, so as to promote the company to accelerate the pace and process of technological innovation and further enhance its core competitiveness in the market.

High-tech enterprises are the highest honors and qualifications recognized by the state. Applying for the title of "high-tech enterprise" requires many forward-looking conditions, including but not limited to: the enterprise must own its own intellectual property rights, and have the invention patents of high-tech products; The human resource structure is reasonable, and the R&D personnel should exceed a certain proportion; The enterprise innovation ability is strong... The title of "high-tech enterprise" reflects the scientific and technological research and development ability and innovation ability of Loqi Biology.

About novamab

Luoqi Biology is the world's leading research and development enterprise of innovative nano antibody drugs. The company was founded in Shanghai International Medical Park, with a research and development and production base of more than 1000 square meters and a unique camel breeding base. Luoqi Biological has independently created five core technology platforms based on nano-antibody: nano-antibody rapid screening platform, Pichia pastoris CMC process development platform, inhaled macromolecular drug research and development platform, nano-antibody long-acting platform and nano-antibody dual-antibody platform, all of which have very unique industry advantages. At present, the company is mainly developing products to cover popular targets such as respiration, ophthalmology and cancer, and has developed product research and development strategies for innovative application scenarios to improve drug utilization and patient compliance.